Streetbeat News

Price Targets

ACCD

Truist Securities analyst Jailendra Singh has reaffirmed a Buy rating on Accolade (NASDAQ:ACCD) and increased the price target from $15 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:32 pm

AMZN

Amazon.com's stock is trading higher following BMO's initiation of coverage with an Outperform rating and a price target of $200.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:28 pm

BFC

Piper Sandler analyst Nathan Rice has initiated coverage on Bank First (NASDAQ:BFC) with a Neutral rating and set a price target of $88 for the stock.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:26 pm

CRWD

CrowdStrike's stock (CRWD) has seen an uptick after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and increased the price target from $203 to $304.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:23 pm

VLTO

Argus Research analyst John Eade has initiated coverage on Veralto (NYSE:VLTO) with a Buy rating and set a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:21 pm

FTNT

Citigroup analyst Fatima Boolani has downgraded Fortinet (NASDAQ:FTNT) from Buy to Neutral while increasing the price target from $60 to $62.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:19 pm

RMD

ResMed's stock (RMD) is trading higher following JP Morgan's decision to maintain an Overweight rating and increase the price target from $160 to $195.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:16 pm

AMAM

B. Riley Securities analyst Yuan Zhi has downgraded Ambrx Biopharma (AMAM) from Buy to Neutral but increased the price target from $26 to $28.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:08 pm

PLXS

Sidoti & Co. analyst Anja Soderstrom downgraded Plexus (NASDAQ:PLXS) from Buy to Neutral and set a price target of $112.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:05 pm

RVNC

Goldman Sachs analyst Chris Shibutani has downgraded Revance Therapeutics (RVNC) from Buy to Neutral and reduced the price target from $30 to $8.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:03 pm